BioPharma Resources

Drug Trial Radar · NCT07140809

a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia

a Multiple-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Escalation Phase Ib/Ⅱa Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetic Characteristics of JMT202 Injection in Chinese Participants With Hypertriglyceridemia

Last checked: Nov 19, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Sep 9, 2025

Primary completion

Jul 31, 2026

Study completion Oct 1, 2026

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
Aug 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and tolerability of multiple subcutaneous injections of JMT202 injection in Chinese participants with hypertriglyceridemia

Conditions

  • Hypertriglyceridemia

Interventions

  • JMT202 injectionBiological

    Subcutaneous injection

  • PlaceboOther

    Matching Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence and severity of TEAETime frame: Day 1 to 99
  2. Number of participants with vital sign abnormalitiesTime frame: Day 1 to 99
  3. Number of participants with physical examination abnormalitiesTime frame: Day 1 to 99
  4. Number of participants with laboratory tests abnormalitiesTime frame: Day 1 to 99
  5. Number of participants with 12-lead electrocardiogram abnormalitiesTime frame: Day 1 to 99
  6. Number of participants with injection site reactions abnormalitiesTime frame: Day 1 to 63

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Hospital of Peking University

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.